Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders. The company's product candidates also comprise Selective 5-HT4 Agonist for treating gastrointestinal motility disorders; Gut-selective Pan-Janus Kinase Inhibitor Program for treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TD-0714 and Neprilysin Inhibitor Program, which have completed Phase I clinical studies for heart failure and chronic kidney disease, including diabetic nephropathy. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-808-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.37 million
Profitability
Miscellaneous
Employees363
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions
What is Theravance Biopharma's stock symbol?
Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
How were Theravance Biopharma's earnings last quarter?
Theravance Biopharma Inc (NASDAQ:TBPH) issued its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.18) by $0.14. The biopharmaceutical company had revenue of $5.34 million for the quarter, compared to analysts' expectations of $16.45 million. Theravance Biopharma had a negative return on equity of 2,632.27% and a negative net margin of 388.61%. View Theravance Biopharma's Earnings History.
When is Theravance Biopharma's next earnings date?
What price target have analysts set for TBPH?
4 Wall Street analysts have issued 12-month price targets for Theravance Biopharma's shares. Their forecasts range from $38.00 to $55.00. On average, they expect Theravance Biopharma's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 144.0% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.
What is the consensus analysts' recommendation for Theravance Biopharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.
What are Wall Street analysts saying about Theravance Biopharma stock?
Here are some recent quotes from research analysts about Theravance Biopharma stock:
- 1. Cantor Fitzgerald analysts commented, ". We believe it is a good time to take another look at TBPH given its inexpensive valuation, and ahead of important catalysts this year. We also note that TBPH’s cash and equivalents totaled $517.1MM as of 12/31/18. It appears well-positioned to receive over $1B in milestones and payments, but its market cap is only ~$1.3B. Therefore, we think the peak sales potential of TBPH’s organ-selective Trelegy, are all underappreciated. Our positive investment thesis supports our OW rating and 12-month PT of $55." (4/12/2019)
- 2. According to Zacks Investment Research, "Theravance reported narrower-than-expected loss in Q4. Also, revenues beat estimates. The company received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. Formal launch activities of Yupelri are currently underway. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have underperformed the industry so far this year." (3/13/2019)
Has Theravance Biopharma been receiving favorable news coverage?
News articles about TBPH stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Theravance Biopharma earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Theravance Biopharma's key competitors?
Some companies that are related to Theravance Biopharma include TESARO (TSRO), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), American Brivision (Holding) (ABVC), Evotec (EVTCY), Blueprint Medicines (BPMC), ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD) and Biohaven Pharmaceutical (BHVN).
What other stocks do shareholders of Theravance Biopharma own?
Who are Theravance Biopharma's key executives?
Theravance Biopharma's management team includes the folowing people:
- Mr. Rick E. Winningham, Chairman & CEO (Age 59)
- Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)
- Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
- Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)
- Mr. Vijay Sabesan, Sr. VP of Technical Operations
Who are Theravance Biopharma's major shareholders?
Theravance Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.62%), Northern Trust Corp (0.98%), Geode Capital Management LLC (0.97%), Jacobs Levy Equity Management Inc. (0.48%), Goldman Sachs Group Inc. (0.47%) and Charles Schwab Investment Management Inc. (0.43%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Frank Pasqualone, Henrietta Fore, Philip D Worboys, Renee D Gala, Rick E Winningham and Sharathchandra S Hegde. View Institutional Ownership Trends for Theravance Biopharma.
Which major investors are selling Theravance Biopharma stock?
TBPH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Ibex Investors LLC, California Public Employees Retirement System, California State Teachers Retirement System, American International Group Inc., Northern Trust Corp and Rhumbline Advisers. Company insiders that have sold Theravance Biopharma company stock in the last year include Bradford J Shafer, Donal O'connor, Philip D Worboys, Renee D Gala and Sharathchandra S Hegde. View Insider Buying and Selling for Theravance Biopharma.
Which major investors are buying Theravance Biopharma stock?
TBPH stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Jacobs Levy Equity Management Inc., Geode Capital Management LLC, Goldman Sachs Group Inc., Tibra Equities Europe Ltd, State of Wisconsin Investment Board, Nisa Investment Advisors LLC and BNP Paribas Arbitrage SA. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Frank Pasqualone, Henrietta Fore and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.
How do I buy shares of Theravance Biopharma?
Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Theravance Biopharma's stock price today?
One share of TBPH stock can currently be purchased for approximately $19.2625.
How big of a company is Theravance Biopharma?
Theravance Biopharma has a market capitalization of $1.08 billion and generates $60.37 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.
What is Theravance Biopharma's official website?
How can I contact Theravance Biopharma?
Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]
MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
